라미부딘 내성 만성 B형 간염 환자에서 라미부딘과 아데포비어 병합요법
Lamivudine and adefovir combination therapy in lamivudine-resistant HBeAg-positive chronic hepatitis B patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The introduction of lamivudine (LAM) has opened a new era for the treatment of chronic hepatitis B (CHB). However, the major drawback of LAM, which currently limits its use as first-line therapy, is the high rate of occurrence of drug resistance. In patients with LAM-resistant CHB, recent long-term findings have indicated that adding adefovir (ADV) to ongoing LAM therapy was more beneficial than switching to ADV alone, because the former showed a diminished rate of resistance to ADV with a well-tolerated safety profile. Above all, the most important strategy for CHB treatment must be to use a potent first-line antiviral with high genetic barriers to resistance in order to prevent the development of multidrug resistance.
Abstract
The introduction of lamivudine (LAM) has opened a new era for the treatment of chronic hepatitis B (CHB). However, the major drawback of LAM, which currently limits its use as first-line therapy, is the high rate of occurrence of drug resistance. In patients with LAM-resistant CHB, recent long-term findings have indicated that adding adefovir (ADV) to ongoing LAM therapy was more beneficial than switching to ADV alone, because the former showed a diminished rate of resistance to ADV with a well-tolerated safety profile. Above all, the most important strategy for CHB treatment must be to use a potent first-line antiviral with high genetic barriers to resistance in order to prevent the development of multidrug resistance.
참고문헌 (13)
- Locarnini S, "Molecular virology and the development of resistant mutants: implications for therapy", Semin Liver Dis, 25(1), pp.9~19 (2005)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- "J Hepatol", 2007, S294~
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Pellicelli AM, "Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study", Clin Ther, 30, pp.317~323 (2008)
- Buti M, "Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients", J Hepatol, 47, pp.366~372 (2007)
- Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
- Shim JH, "Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone", Hepatology, 50, pp.1064~1071 (2009)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Villet S, "of hepatitis B virus rtA181V", T mutants on hepatitis B treatment failure, 2008, pp.48, 747~755
- van Bommel F, "Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection", Hepatology, 40, pp.1421~1425 (2004)
- Hann HW, "Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)", Hepatol Int, 2, pp.244~249 (2008)